Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- IMCAS Refresher: Aging Sciences/Plastic Surgery
Trends in aesthetic and regenerative medicine
- Pelargonium sidoides
Scoping review sheds light on the multifaceted spectrum of effects
- New evidence on genetics, pathophysiology and clinical significance
Migraine with and without aura – two different entities?
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights